Travel vaccines—priorities determined by incidence and impact

Abstract

Background Infectious disease epidemiology is continuously shifting. While travel has been disrupted by the COVID-19 pandemic and travel-related epidemiological research experienced a pause, further shifts in vaccine-preventable diseases (VPD) relevant for travellers have occurred. Methods We conducted a literature search on the epidemiology of travel-related VPD and synthesized data for each disease with a focus on symptomatic cases and on the impact of the respective infection among travellers, considering the hospitalization rate, disease sequela and case fatality rate (CFR). We present new data and revised best estimates on the burden of VPD relevant for decisions on priorities in travel vaccines. Results COVID-19 has emerged to be a top travel-related risk and influenza remains high in the ranking with an estimated incidence at 1% per month of travel. Dengue is another commonly encountered infection among international travellers with estimated monthly incidence of 0.5–0.8% among non-immune exposed travellers; the hospitalized proportion was 10 and 22%, respectively according to two recent publications. With recent yellow fever outbreaks particularly in Brazil, its estimated monthly incidence has risen to > 0.1%. Meanwhile, improvements in hygiene and sanitation have led to some decrease in foodborne illnesses; however, hepatitis A monthly incidence remains substantial in most developing regions (0.001–0.01%) and typhoid remains particularly high in South Asia (>0.01%). Mpox, a newly emerged disease that demonstrated worldwide spread through mass gathering and travel, cannot be quantified regarding its travel-related risk. Conclusion The data summarized may provide a tool for travel health professionals to prioritize preventive strategies for their clients against VPD. Updated assessments on incidence and impact are ever more important since new vaccines with travel indications (e.g. dengue) have been licensed or are undergoing regulatory review.

Reiseimpfungen – Hinweise und Empfehlungen

“…Bei einem Biss, Kratzer oder einem Schleimhautkontakt mit Blut oder Speichel eines infizierten Säugetiers besteht ein Tollwutrisiko. Verletzungen durch potenziell tollwütige Tiere sind ein relevantes reisemedizinische Problem, die Inzidenzrate wird auf rund 0,5-1,5 % pro Reisemonat geschätzt [13,74]. In einer Studie des GeoSentinel-Netzwerks wurden die meisten Tierkontakte von Reisenden aus Asien gemeldet; am häufigsten beteiligte Tierspezies waren Hunde, Affen und Katzen [75], wobei das tatsächliche Hauptrisiko von Hunden ausgeht, die ursächlich für über 99 % der weltweiten humanen Tollwutfälle sind.…”